An Overview of DNA Vaccines Development Studies Against Toxoplasma gondii

ABSTRACT

Toxoplasma gondii (T. gondii) is an obligate intracellular parasite that can infect almost all warm-blooded animals, including humans, and one-third of the global population is thought to be infected with this parasite. Infection can occur through consumption of contaminated food, contact with an infected host, or congenital transmission. While toxoplasmosis is asemptomatic in people with a healthy immune system, it can cause severe infections in people with a suppressed immune system or with immunodeficiency. In addition to causing diseases in humans, it also causes infections in livestock and may result in stillbirth and abortion in sheep and goats. There is no 100% effective medicine or vaccination against the parasite that causes major clinical symptoms and financial losses. There is a need for an effective, safe, and durable vaccine that can provide protective immunity for use in humans and animals. Vaccination studies against toxoplasmosis have gathered speed since the 1990s. Today, studies can be carried out to develop effective and safe vaccines depending on the developments in molecular biology, biotechnology, and immunology. DNA vaccines are a promising vaccine platform against toxoplasmosis because they are easy to produce, they are safe, they do not need a cold chain, and they can stimulate both humoral and cellular immune responses. This review provides an overview of the complex life cycle, pathogenesis, and epidemiology of the parasite; the immune response that develops in the host against the infection it causes; and the DNA vaccines developed against toxoplasmosis and these vaccines.